(firstQuint)A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer.

 This is a Phase II, open label, single arm, multicenter study of NK012 in patients with locally advanced non-resectable and metastatic breast cancer with ER-negative, PR negative and HER2-negative phenotype.

 NK012 will be administered by infusion over 30 minutes once every 28 days (on Day 1 of each cycle).

 Patients will be screened for UGT1A1 polymorphism prior to enrollment in order to determine their starting dose.

.

 A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer@highlight

The purpose of this study is to determine whether NK012 is safe and effective in the treatment of advanced and metastatic triple negative breast cancer.

